Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
73 results about "Tissue factor pathway inhibitor" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Tissue factor pathway inhibitor (or TFPI) is a single-chain polypeptide which can reversibly inhibit Factor Xa (Xa). While Xa is inhibited, the Xa-TFPI complex can subsequently also inhibit the FVIIa-tissue factor complex. TFPI contributes significantly to the inhibition of Xa in vivo, despite being present at concentrations of only 2.5 nM.
TFPI inhibitors and methods of use
ActiveUS20100173847A1Improves TFPI-regulated thrombin generationFactor VIIPeptide-nucleic acidsMedicineThrombin activity
The invention provides peptides that bind Tissue Factor Pathway Inhibitor (TFPI), including TFPI-inhibitory peptides, and compositions thereof. The peptides may be used to inhibit a TFPI, enhance thrombin formation in a clotting factor-deficient subject, increase blood clot formation in a subject, and / or treat a blood coagulation disorder in a subject.
Owner:TAKEDA PHARMA CO LTD
Antibodies Against Tissue Factor Pathway Inhibitor
ActiveUS20110318356A1Shorten clotting timeImmunoglobulins against blood coagulation factorsFungiCoagulopathyTissue factor pathway inhibitor
The invention relates to antibodies that specifically bind to tissue factor pathway inhibitor (TFPI) and that reduce the clotting time of blood. Such antibodies have utility in the treatment of subjects with a coagulopathy.
Owner:NOVO NORDISK AS
Process for preparing tissue factor pathway inhibitor
InactiveUS6300100B1Microorganism based processesRecombinant DNA-technologyBiotechnologySulfated polysaccharides
In a process for preparing Tissue Factor Pathway Inhibitor (TFPI) by the genetically engineered technique by the use of a transformed animal cell wherein a DNA encoding human TFPI is introduced, the improvement which comprises culturing said transformed animal cell in a culture medium supplemented with a sulfated polysaccharide to protect an intact TFPI produced by said transformed animal cell from cleavage by proteases present in the culture medium.
Owner:JURIDICAL FOUND THE CHEMO SERO THERAPEUTIC RES INST
Regulation of Tissue Factor Activity by Protein S and Tissue Factor Pathway Inhibitor
InactiveUS20080161425A1Enhanced inhibitory effectReduce inhibitionCompound screeningBiocideThrombin activityProtein S
The present invention relates to methods for the identification of compounds that increase or decrease the inhibitory effect of TFPI on tissue factor activity and / or Factor Xa activity and / or thrombin formation. The invention also relates to methods for the identification of compounds that increase or decrease the co-factor activity of Protein S in TFPI-mediated inhibition of tissue factor and / or Factor Xa activity. This invention also relates to a pharmaceutical composition comprising the compounds identifiable by such methods. The invention also relates to methods for the regulation of tissue factor activity by influencing the interaction between Protein S and Tissue Factor Pathway Inhibitor.
Owner:MAASTRICHT UNIVERSITY
Use of TFPI to Treat Severe Bacterial Infections
Methods for prophylactically or therapeutically treating a patient at risk of developing or diagnosed as having a severe bacterial infection involving administration of tissue factor pathway inhibitor (TFPI) or a TFPI analog to patients suffering from or at risk of developing this condition. The methods involve the use of continuous intravenous infusion of TFPI or a TFPI analog at low doses to avoid adverse side effects.
Owner:NOVARTIS AG
TFPI inhibitors and methods of use
ActiveUS20120028901A1Improves TFPI-regulated thrombin generationIncrease the number ofPeptide/protein ingredientsLibrary screeningMedicineThrombin activity
The invention provides peptides that bind Tissue Factor Pathway Inhibitor (TFPI), including TFPI-inhibitory peptides, and compositions thereof. The peptides may be used to inhibit a TFPI, enhance thrombin formation in a clotting factor-deficient subject, increase blood clot formation in a subject, treat a blood coagulation disorder in a subject, purify TFPI, and identify a TFPI-binding compound.
Owner:TAKEDA PHARMA CO LTD
TFPI inhibitors and methods of use
ActiveUS8450275B2Improves TFPI-regulated thrombin generationIncrease the number ofCompound screeningApoptosis detectionClot formationTissue factor pathway inhibitor
Owner:TAKEDA PHARMA CO LTD
Antibodies against tissue factor pathway inhibitor
ActiveUS8361469B2Shorten clotting timeImmunoglobulins against blood coagulation factorsPeptide/protein ingredientsCoagulopathyTissue factor pathway inhibitor
The invention relates to antibodies that specifically bind to tissue factor pathway inhibitor (TFPI) and that reduce the clotting time of blood. Such antibodies have utility in the treatment of subjects with a coagulopathy.
Owner:NOVO NORDISK AS
TFPI inhibitors and methods of use
ActiveUS8466108B2Improves TFPI-regulated thrombin generationPeptide-nucleic acidsFactor VIIMedicineThrombin activity
The invention provides peptides that bind Tissue Factor Pathway Inhibitor (TFPI), including TFPI-inhibitory peptides, and compositions thereof. The peptides may be used to inhibit a TFPI, enhance thrombin formation in a clotting factor-deficient subject, increase blood clot formation in a subject, and / or treat a blood coagulation disorder in a subject.
Owner:TAKEDA PHARMA CO LTD
Aptamers to tissue factor pathway inhibitor and their use as bleeding disorder therapeutics
ActiveUS20110281938A1Reduce complicationsEliminate side effectsOrganic active ingredientsSugar derivativesDiseaseSide effect
Owner:BAXALTA GMBH
Ixodes scapularis tissue factor pathway inhibitor
InactiveUS7078508B2BacteriaPeptide/protein ingredientsTissue factor pathway inhibitorAnticoagulant activity
Ixolaris, a novel protein with anticoagulant activity is described. Ixolaris can be isolated from the salivary glands of ticks or made by recombinant methods using various DNA expression techniques.
Owner:HEALTH & HUMAN SERVICES DEPT OF THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SEC
Monoclonal antibodies against tissue factor pathway inhibitor (TFPI)
InactiveCN102143979AShorten bleeding timeImmunoglobulins against blood coagulation factorsAntibody mimetics/scaffoldsMonoclonal antibodyTissue factor pathway inhibitor
Isolated monoclonal antibodies that bind human tissue factor pathway inhibitor (TFPI) and the isolated nucleic acid molecules encoding them are provided. Pharmaceutical compositions comprising the anti-TFPI monoclonal antibodies and methods of treating deficiencies or defects in coagulation by administration of the antibodies are also provided. Methods of producing the antibodies are also provided.
Owner:BAYER HEALTHCARE LLC
Method of treatment of hemorrhagic disease using a factor VIIa/tissue factor inhibitor
ActiveUS7132398B2Decrease or prevent said coagulopathy and/or inflammatory responseBiocidePeptide/protein ingredientsFactor VIIaNematode
The present invention provides methods of treating hemorrhagic fevers where selective inhibitors of fVIIa / TF are used as a treatment for hemorrhagic fevers and have therapeutic effects which include ameliorating and / or preventing coagulopathy and inflammatory responses. These inhibitors include certain proteins which are part of a family termed Nematode-Extracted Anticoagulant Proteins (“NAPs”). Other inhibitors include Tissue Factor Pathway Inhibitor (“TFPI”) and TFPI analogs.
Owner:DENDREON PHARMA LLC
Monoclonal antibodies against tissue factor pathway inhibitor (TFPI)
InactiveCN103797030AImmunoglobulins against animals/humansAntibody ingredientsEpitopeMonoclonal antibody
Isolated monoclonal antibodies that bind to specific epitopes of human tissue factor pathway inhibitor (TFPI) and the isolated nucleic acid molecules encoding them are provided. Pharmaceutical compositions comprising the anti-TFPI monoclonal antibodies and methods of treating deficiencies or defects in coagulation by administration of the antibodies are also provided.
Owner:BAYER HEALTHCARE LLC
Tissue factor pathway inhibitor (TFPI), preparation method thereof and application thereof
InactiveCN102070711AStable expressionEfficient and stable expressionAntibacterial agentsPeptide/protein ingredientsDiseaseThiogalactosides
The invention relates to the field of microbiology, in particular to a tissue factor pathway inhibitor (TFPI), a preparation method thereof and application thereof. A TFPI-1 is represented by the amino acid sequence SEQ ID No.1 in the sequence list; and a TFPI-2 is represented by the amino acid sequence SEQ ID No.2 in the sequence list. The preparation method comprises: converting colibacillus BL21 (DE3) by plasmids pE15TFPI1 and pE15TFP2 to obtain BL21 / pE15TFPI1 and BL21 / pE15TFPI2 respectively; inducing the obtained products with isopropyl-beta-D-thiogalactoside; and purifying recombinant proteins through affinity chromatography to obtain TFPI-1 and TFPI-2. The TFPI has a high-efficiency sterilization effect and therefore can resist to bacterial infection and be used for disease prevention and treatment. The TFPI provided by the invention can effectively crack many pathogenic bacteria so as to inhibit bacterial infection.
Owner:INST OF OCEANOLOGY - CHINESE ACAD OF SCI
Aptamers to Tissue Factor Pathway Inhibitor and Their Use as Bleeding Disorder Therapeutics
ActiveUS20110098345A1Reduce complicationsEliminate side effectsOrganic active ingredientsSugar derivativesSide effectSurgery
Owner:TAKEDA PHARMA CO LTD
Prevention and treatment of tumor growth, metastasis, and thromboembolic complications in cancer patients
InactiveUS6908907B2Preventing and treating thrombosisInhibit platelet activationBiocidePeptide/protein ingredientsLymphatic SpreadRegimen
This invention provides for the prevention and treatment of tumor growth, metastasis, and cancer-mediated thrombosis through the administration, in combination, of a short or long acting GPIIb / IIIa antagonist (A) and anticoagulant (B) that might include the following: UFH or low molecular weight heparin, (LMWH), ultra LMWH, pentasaccharide or direct anti-Xa or direct anti-IX / IXa, direct anti-IIa (thrombin) or tissue factor pathway inhibitor (TFPI) by any means that produces contact of the agents with their site of action wherein at least one of the components of each of these combinations is given in reduced amount. This combined formulation could be used as a stand-alone regimen or in conjunction with other therapies (chemotherapy, radiotherapy, angiogenesis inhibitors, . . . ), and pre- & post-tumor surgery in the prevention and treatment of cancer associated metastasis, angiogenesis, tumor growth, and thrombosis.
Owner:EL NAGGAR MAWAHEB M +1
Antibodies capable of specifically binding two epitopes on tissue factor pathway inhibitor
The application discloses a combination of two monospecific TFPI antibodies, wherein one antibody is capable of specifically binding TFPI (1-181) and the other antibody is capable of specifically binding TFPI (182-276), as well as bispecific anti-TFPI antibodies derived from two such monospecific antibodies. Both the combination of the two monospecific antibodies and the bispecific antibody strongly enhance thrombin generation by neutralising full length TFPIα, even where the concentration of TFPI is abnormally elevated.
Owner:NOVO NORDISK AS
Antibodies That Are Capable of Specifically Binding Tissue Factor Pathway Inhibitor
ActiveUS20130142804A1Suitable for useImmunoglobulins against cell receptors/antigens/surface-determinantsAntibody ingredientsNucleotideFactor ii
The invention relates to antibodies that are capable of specifically binding tissue factor pathway inhibitor (TFPI), neutralising free TFPI and reducing the clotting time of blood. Furthermore, the invention relates to polynucleotides that encode such antibodies and to cells that comprise the polynucleotides or that express the antibodies of the invention. Such antibodies have utility in the treatment of subjects with a coagulopathy, alone as well as in combination with a second agent.
Owner:NOVO NORDISK AS
Treatment of severe pneumonia by administration of tissue factor pathway inhibitor (TFPI)
Methods for prophylactically or therapeutically treating severe pneumonia involve administration of tissue factor pathway inhibitor (TFPI) or a TFPI analog to patients suffering from or at risk of developing this condition. The methods involve the use of continuous intravenous infusion of TFPI or a TFPI analog, preferably at low doses to avoid adverse side effects.
Owner:NOVARTIS VACCINES & DIAGNOSTICS INC
Coagulation and fibrinolytic cascades modulator
InactiveCN101184775APeptide/protein ingredientsMicrobiological testing/measurementFactor iiPolyphosphate
The invention provides a thromboplastin reagent comprising: tissue factor, a phospholipid and a polyphosphate that acts as a blocker of tissue factor pathway inhibitor (TFPI). Also provided are a composition for promoting clotting comprising polyphosphate, and a reagent for a clotting assay also comprising polyphosphate together with an activator of clotting. Methods for stopping or slowing wound bleeding and fibrinolysis using compositions comprising polyphosphate are also disclosed.
Owner:THE BOARD OF TRUSTEES OF THE UNIV OF ILLINOIS
Aptamers to tissue factor pathway inhibitor and their use as bleeding disorder therapeutics
ActiveUS8252913B2Reduce complicationsEliminate the effects ofOrganic active ingredientsSugar derivativesAptamerDisease
Owner:TAKEDA PHARMA CO LTD
Aptamers to tissue factor pathway inhibitor and their use as bleeding disorder thereapeutics
ActiveUS20120190834A1Reduce complicationsEliminate the effects ofSugar derivativesPeptide/protein ingredientsAptamerDisease
Owner:BAXALTA GMBH
Treatment of severe community-acquired pneumonia by administration of tissue factor pathway inhibitor (tfpi)
Methods for prophylactically or therapeutically treating severe pneumonia involve administration of tissue factor pathway inhibitor (TFPI) or a TFPI analog to patients suffering from or at risk of developing this condition. The methods involve the use of continuous intravenous infusion of TFPI or a TFPI analog, preferably at low doses to avoid adverse side effects.
Owner:CHIRON CORP
Antibodies that are capable of specifically binding tissue factor pathway inhibitor
The invention relates to antibodies that are capable of specifically binding tissue factor pathway inhibitor (TFPI), neutralizing free TFPI and reducing the clotting time of blood. Furthermore, the invention relates to polynucleotides that encode such antibodies and to cells that comprise the polynucleotides or that express the antibodies of the invention. Such antibodies have utility in the treatment of subjects with a coagulopathy, alone as well as in combination with a second agent.
Owner:NOVO NORDISK AS
Antibodies Against Tissue Factor Pathway Inhibitor (TFPI)
InactiveUS20110268745A1Shorten clotting timeImmunoglobulins against blood coagulation factorsSugar derivativesDiseaseAntiendomysial antibodies
The invention relates to antibodies that specifically bind to tissue factor pathway inhibitor (TFPI) and that reduce clotting time in (a) human FVIII-deficient plasma and / or (b) human whole blood. Such antibodies have utility in the treatment of bleeding disorders and in the stimulation of blood clotting.
Owner:NOVO NORDISK AS
Method for screening micropore plate of tissue factor approach restrainer and uses thereof
InactiveCN101201314AReduce dosageLow costMicrobiological testing/measurementMaterial analysis by optical meansFreeze thawingScreening method
The invention relates to the field of medicament, in particular to an in-vitro microplate-based screening method of tissue factor (TF) pathway inhibitors, and is characterized in that the invention comprises the following steps: incubating cells and the medicament to be measured together; getting cell lysis solution after freeze thaw, blowing and beating; putting the cell lysis solution on the microplate for incubation; adding human prothrombin complex solution for incubation; adding chromogenic substrate solution in the reactant liquor for incubation; measuring the value of absorbance with a micro-plate reader of 405nm. The invention also discloses some tissue factor pathway inhibitors screened out by using the method, such as hydroxygenkwanin, ruscogenin, quercetinic acid, ginsenoside Rb1, ginsenoside or diosgenin and so on.
Owner:CHINA PHARM UNIV
Method of treatment of hemorrhagic disease using a factor VIIa/tissue factor inhibitor
ActiveUS20040266672A1Reduce incidence deathPrevent coagulationBiocidePeptide/protein ingredientsFactor VIIaNematode
The present invention provides methods of treating hemorrhagic fevers where selective inhibitors of fVIIa / TF are used as a treatment for hemorrhagic fevers and have therapeutic effects which include ameliorating and / or preventing coagulopathy and inflammatory responses. These inhibitors include certain proteins which are part of a family termed Nematode-Extracted Anticoagulant Proteins ("NAPs"). Other inhibitors include Tissue Factor Pathway Inhibitor ("TFPI") and TFPI analogs.
Owner:DENDREON PHARMA LLC
Antibodies capable of specifically binding two epitopes on tissue factor pathway inhibitor
The application discloses a combination of two monospecific TFPI antibodies, wherein one antibody is capable of specifically binding TFPI (1-181) and the other antibody is capable of specifically binding TFPI (182-276), as well as bispecific anti-TFPI antibodies derived from two such monospecific antibodies. Both the combination of the two monospecific antibodies and the bispecific antibody strongly enhance thrombin generation by neutralising full length TFPI[alpha], even where the concentration of TFPI is abnormally elevated.
Owner:NOVO NORDISK AS
Aptamers to tissue factor pathway inhibitor and their use as bleeding disorder therapeutics
InactiveUS20130267584A1Reduce gapExtended half-lifeGenetic material ingredientsBlood disorderAptamerFactor ii
Owner:BAXTER INT INC +1
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com